MVCD3
MCID: MCR113
MIFTS: 45

Microvascular Complications of Diabetes 3 (MVCD3) malady

Categories: Genetic diseases, Nephrological diseases, Cardiovascular diseases, Eye diseases, Neuronal diseases

Aliases & Classifications for Microvascular Complications of Diabetes 3

Aliases & Descriptions for Microvascular Complications of Diabetes 3:

Name: Microvascular Complications of Diabetes 3 54 66 29 13 38
Diabetic Nephropathy 38 66 69
Diabetic End-Stage Renal Disease 66
Diabetic Nephropathies 52
Mvcd3 66

Classifications:



External Ids:

OMIM 54 612624
MeSH 42 D048909

Summaries for Microvascular Complications of Diabetes 3

UniProtKB/Swiss-Prot : 66 Microvascular complications of diabetes 3: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary : Microvascular Complications of Diabetes 3, also known as diabetic nephropathy, is related to microvascular complications of diabetes 7 and microvascular complications of diabetes 1. An important gene associated with Microvascular Complications of Diabetes 3 is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are p70S6K Signaling and Peptide hormone metabolism. The drugs Spironolactone and Moxonidine have been mentioned in the context of this disorder. Affiliated tissues include Kidney, and related phenotypes are behavior/neurological and cardiovascular system

Description from OMIM: 612624

Related Diseases for Microvascular Complications of Diabetes 3

Diseases in the Microvascular Complications of Diabetes 1 family:

Microvascular Complications of Diabetes 4 Microvascular Complications of Diabetes 7
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 2
Microvascular Complications of Diabetes 5 Microvascular Complications of Diabetes 3

Diseases related to Microvascular Complications of Diabetes 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 135)
id Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 7 11.5
2 microvascular complications of diabetes 1 11.5
3 microvascular complications of diabetes 6 11.5
4 microvascular complications of diabetes 2 11.5
5 microvascular complications of diabetes 5 11.5
6 microvascular complications of diabetes 4 11.5
7 diabetic angiopathy 10.8
8 endotheliitis 10.3
9 penile cancer, childhood 10.3 ACE AGT
10 submucous uterine fibroid 10.2 ALB INS
11 congenital nystagmus 10.2 ACE ALB
12 hypersensitivity syndrome, carbamazepine-induced 10.2 ALB INS
13 schizotypal personality disorder 10.2 ACE AGT ALB
14 iris disease 10.1 ACE AGT AGTR1
15 cascade stomach 10.1 ACE AGT AGTR1
16 hyperuricemic nephropathy, familial juvenile 2 10.1 ACE AGT AGTR1
17 eastern equine encephalitis 10.1 ACE AGT AGTR1
18 aplasia cutis congenita recessive 10.1 ACE AGT AGTR1
19 laryngostenosis 10.1 ACE AGT AGTR1
20 petrositis 10.1 ACE AGTR1 ALB
21 joint disorders 10.1 ACE AGTR1 INS
22 cerebral convexity meningioma 10.1 ACE AGT AGTR1
23 cataract 10.1 ALB INS
24 body dysmorphic disorder 10.1 ACE ALB INS
25 transient refractive change 10.1 ACE ALB NPHS1
26 cervix small cell carcinoma 10.1 ACE AGTR1 INS
27 spondyloarthropathy 2 10.1 ACE ALB NAGLU
28 dilated cardiomyopathy 10.0 ACE AKR1B1 INS
29 chronic myocardial ischemia 10.0 ACE AGT ALB INS
30 malignant hyperthermia susceptibility 1 10.0 ACE AGT ALB NPHS1
31 fissured tongue 10.0 AKR1B1 ALB INS
32 prostate neuroendocrine neoplasm 10.0 ACE AGT AGTR1 ALB
33 choroiditis 10.0 ACE ALB NAGLU
34 idiopathic panuveitis 10.0 ACE TGFB1
35 cetp-related hyperalphalipoproteinemia 10.0 ACE AGT AGTR1 INS
36 rumination disorder 10.0 AKR1B1 INS
37 glomerulonephritis 10.0
38 hemiplegia 10.0 ALB NAGLU NPHS1
39 eye degenerative disease 10.0 ACE AGT AGTR1 CTGF
40 brain stem glioma 10.0 AKR1B1 ALB INS
41 miliaria 10.0 CTGF TGFB1
42 peroneal neuropathy 10.0 ACE AKR1B1 ALB INS
43 gliosarcoma 10.0 ALB NAGLU
44 kidney disease 9.9
45 pericarditis 9.9 ACE AGER ALB INS
46 acute chest syndrome 9.9 ACE ALB TGFB1
47 geleophysic dysplasia 2 9.9 CTGF TGFB1
48 pulmonary valve insufficiency 9.9 ACE CTGF TGFB1
49 renal fibrosis 9.9
50 end stage renal failure 9.9

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 3:



Diseases related to Microvascular Complications of Diabetes 3

Symptoms & Phenotypes for Microvascular Complications of Diabetes 3

Clinical features from OMIM:

612624

MGI Mouse Phenotypes related to Microvascular Complications of Diabetes 3:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.01 ACE AGER AGT AGTR1 AKR1B1 INS
2 cardiovascular system MP:0005385 9.97 ACE AGER AGT AGTR1 CTGF INS
3 growth/size/body region MP:0005378 9.97 ACE AGER AGT AGTR1 AKR1B1 CTGF
4 homeostasis/metabolism MP:0005376 9.96 ACE AGER AGT AGTR1 AKR1B1 ALB
5 adipose tissue MP:0005375 9.83 ACE AGT AGTR1 INS TGFB1
6 mortality/aging MP:0010768 9.65 NAGLU NPHS1 TGFB1 ACE AGT AGTR1
7 liver/biliary system MP:0005370 9.63 ACE AGT ALB INS NAGLU TGFB1
8 renal/urinary system MP:0005367 9.32 INS NAGLU NPHS1 TGFB1 ACE AGER

Drugs & Therapeutics for Microvascular Complications of Diabetes 3

Drugs for Microvascular Complications of Diabetes 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 442)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Spironolactone Approved Phase 4,Phase 2,Phase 3,Phase 1 1952-01-7, 52-01-7 5833
2 Moxonidine Approved Phase 4 75438-57-2 4810
3
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
4
Ticlopidine Approved Phase 4 55142-85-3 5472
5
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
6
Amlodipine Approved Phase 4 88150-42-9 2162
7
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
8
Atenolol Approved Phase 4 29122-68-7 2249
9
Clonidine Approved Phase 4 4205-90-7 2803
10
Doxazosin Approved Phase 4 74191-85-8 3157
11
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
12
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3 58-93-5 3639
13
Irbesartan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 138402-11-6 3749
14
Simvastatin Approved Phase 4 79902-63-9 54454
15
Acarbose Approved, Investigational Phase 4,Phase 3 56180-94-0 441184
16
Pioglitazone Approved, Investigational Phase 4,Phase 3 111025-46-8 4829
17
Candesartan Approved Phase 4 139481-59-7 2541
18
Cilnidipine Approved Phase 4 132203-70-4 5282138
19
Fluvastatin Approved Phase 4 93957-54-1 1548972
20
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2 137862-53-4 60846
21
Febuxostat Approved Phase 4 144060-53-7 134018
22
Nitric Oxide Approved Phase 4,Phase 2,Phase 3 10102-43-9 145068
23
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
24
Isosorbide Dinitrate Approved Phase 4 87-33-2 6883
25
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
26
Insulin Glargine Approved Phase 4 160337-95-1
27
Zinc Approved Phase 4,Phase 3,Phase 2 7440-66-6 32051 23994
28
Liraglutide Approved Phase 4,Phase 3 204656-20-2
29
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3 22916-47-8 4189
30
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
31
Insulin Lispro Approved Phase 4 133107-64-9
32
Linagliptin Approved Phase 4,Phase 3 668270-12-0 10096344
33
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
34
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1 53608-75-6
35
Everolimus Approved Phase 4,Phase 3 159351-69-6 6442177
36
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
37
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
38
Sirolimus Approved, Investigational Phase 4,Phase 3 53123-88-9 5284616 6436030 46835353
39
Insulin-glulisine Approved Phase 4 207748-29-6
40
Cilostazol Approved Phase 4 73963-72-1 2754
41
Probucol Approved Phase 4,Phase 2 23288-49-5 4912
42
Telmisartan Approved, Investigational Phase 4,Phase 3,Phase 2 144701-48-4 65999
43
Indapamide Approved Phase 4,Phase 3 26807-65-8 3702
44
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2 75847-73-3 5362032 40466924
45
Enalaprilat Approved Phase 4,Phase 3,Phase 2 76420-72-9 6917719
46
Losartan Approved Phase 4,Phase 3,Phase 2,Early Phase 1 114798-26-4 3961
47
Alprostadil Approved, Investigational Phase 4 745-65-3 149351
48
Lisinopril Approved, Investigational Phase 4,Phase 3,Phase 1 83915-83-7 5362119
49
Nisoldipine Approved Phase 4 63675-72-9 4499
50
Benazepril Approved, Investigational Phase 4,Phase 3 86541-75-5 5362124

Interventional clinical trials:

(show top 50) (show all 634)
id Name Status NCT ID Phase
1 Aldosterone in Diabetic Nephropathy Unknown status NCT00870402 Phase 4
2 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease Unknown status NCT01094769 Phase 4
3 Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
4 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4
5 Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4
6 Effect of Sulodexide on Albuminuria in Chinese Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4
7 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
8 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study) Unknown status NCT01869881 Phase 4
9 Nephropathy In Type 2 Diabetes and Cardio-renal Events Unknown status NCT00535925 Phase 4
10 Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4
11 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4
12 CCB Safety Study in Treatment of Hypertension of ADPKD Unknown status NCT00541853 Phase 4
13 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4
14 The Effect of Uric Acid Lowering in Type 1 Diabetes Unknown status NCT02344602 Phase 4
15 Prevention of Contrast-Induced Nephropathy in Diabetic Patients With Undergoing Coronary Angiography Unknown status NCT00950079 Phase 4
16 A Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria Unknown status NCT00843388 Phase 4
17 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
18 A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care Unknown status NCT00939250 Phase 4
19 Efficacy of Pregabalin in the Management of Chronic Uremic Pruritus Unknown status NCT01073501 Phase 4
20 HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study) Unknown status NCT00106886 Phase 4
21 Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN) Completed NCT00708981 Phase 4
22 Benfotiamine in Diabetic Nephropathy Completed NCT00565318 Phase 4
23 Spironolactone in Diabetic Nephropathy Completed NCT00317954 Phase 4
24 Controlled Study to Evaluate Efficacy and Safety of α-KA Tab With Low Protein Diet (LPD) in Delaying the Progress of Type 2 Diabetic Nephropathy (DN) Completed NCT00363987 Phase 4
25 A Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy Completed NCT01252056 Phase 4
26 INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy Completed NCT00153088 Phase 4
27 Renal Denervation in Diabetic Nephropathy Completed NCT01588795 Phase 4
28 Effect of a Vitamin D Analogue vs Placebo on p-NT-proBNP in Patients With Type 1 DM and Diabetic Nephropathy Completed NCT01331317 Phase 4
29 Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus Completed NCT00419835 Phase 4
30 Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN) Completed NCT01028287 Phase 4
31 The Use of Cilostazol in Patients With Diabetic Nephropathy Completed NCT00272831 Phase 4
32 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy Completed NCT02628106 Phase 4
33 Doxazosin Effects on ABPM in Hypertensive Patients With Diabetic Nephropathy Completed NCT00295555 Phase 4
34 Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy Completed NCT00311870 Phase 4
35 Antiproteinuric Effect of Valsartan and Lisinopril Completed NCT00171574 Phase 4
36 Linkage Consortium for End-Stage Renal Disease Completed NCT00301249 Phase 4
37 Effect of Renin Angiotensin System Blockade on the Fas Antigen (CD95) and Asymmetric Dimethylarginine (ADMA) Levels in Type-2 Diabetic Patients With Proteinuria Completed NCT00893425 Phase 4
38 Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM) Completed NCT00234871 Phase 4
39 Add-on Pentoxifylline to Losartan Versus Increasing Dose of Losartan on NT-PRO BNP in Type 2 Diabetics With Nephropathy Completed NCT03006952 Phase 4
40 1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy Completed NCT00153023 Phase 4
41 A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nep Completed NCT00168857 Phase 4
42 Effect of LIXIsenatide on the Renal System Completed NCT02276196 Phase 4
43 Antiproteinuric Effects of Liraglutide Treatment Completed NCT02545738 Phase 4
44 Glucose in Dialysis Water in Diabetics With Chronic Renal Failure Completed NCT00438503 Phase 4
45 A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT) Completed NCT00235014 Phase 4
46 Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM) Completed NCT00296296 Phase 4
47 FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients Completed NCT01703234 Phase 4
48 Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients Completed NCT01664676 Phase 4
49 The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension Completed NCT00921570 Phase 4
50 Effect of Calcium Channel Blocker on the Serum Fibrobalst Growth Factor-23 (FGF-23) Levels in Type-2 Diabetic Patients With Proteinuria Purpose Completed NCT01738945 Phase 4

Search NIH Clinical Center for Microvascular Complications of Diabetes 3

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Microvascular Complications of Diabetes 3:
Mesenchymal precursor cells for type 2 diabetes
Embryonic/Adult Cultured Cells Related to Microvascular Complications of Diabetes 3:
Mesenchymal Precursor Cells (STRO-3 selected)

Genetic Tests for Microvascular Complications of Diabetes 3

Genetic tests related to Microvascular Complications of Diabetes 3:

id Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes 3 29

Anatomical Context for Microvascular Complications of Diabetes 3

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Microvascular Complications of Diabetes 3:
id Tissue Anatomical CompartmentCell Relevance
1 Kidney Podocyte Layer Podocytes Potential therapeutic candidate, affected by disease

Publications for Microvascular Complications of Diabetes 3

Variations for Microvascular Complications of Diabetes 3

ClinVar genetic disease variations for Microvascular Complications of Diabetes 3:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 ACE NM_000789.3(ACE): c.2306-117_2306-116insAF118569.1: g.14094_14382 insertion risk factor rs4340 GRCh37 Chromosome 17, 61565892: 61565893

Expression for Microvascular Complications of Diabetes 3

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 3.

Pathways for Microvascular Complications of Diabetes 3

GO Terms for Microvascular Complications of Diabetes 3

Cellular components related to Microvascular Complications of Diabetes 3 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 ACE AGER AGT ALB CNDP1 CTGF
2 blood microparticle GO:0072562 9.33 AGT ALB TGFB1
3 extracellular space GO:0005615 9.17 ACE AGT AKR1B1 ALB CTGF INS

Biological processes related to Microvascular Complications of Diabetes 3 according to GeneCards Suite gene sharing:

(show all 32)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.94 AGT CTGF INS TGFB1
2 aging GO:0007568 9.82 AGT CTGF TGFB1
3 kidney development GO:0001822 9.76 ACE AGT AGTR1
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.73 AGT INS TGFB1
5 response to wounding GO:0009611 9.7 AGER CTGF TGFB1
6 regulation of cell growth GO:0001558 9.69 AGT AGTR1 CTGF
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.67 AGER AGT INS TGFB1
8 blood vessel remodeling GO:0001974 9.65 ACE AGT
9 positive regulation of reactive oxygen species metabolic process GO:2000379 9.65 AGT AGTR1
10 positive regulation of protein tyrosine kinase activity GO:0061098 9.65 ACE AGT
11 positive regulation of vasodilation GO:0045909 9.63 AGT INS
12 positive regulation of collagen biosynthetic process GO:0032967 9.63 CTGF TGFB1
13 positive regulation of protein localization to nucleus GO:1900182 9.62 INS TGFB1
14 tissue homeostasis GO:0001894 9.62 AKR1B1 CTGF
15 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.61 AGT TGFB1
16 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.61 AGT AGTR1
17 regulation of vasodilation GO:0042312 9.6 ACE AGTR1
18 low-density lipoprotein particle remodeling GO:0034374 9.59 AGT AGTR1
19 angiotensin maturation GO:0002003 9.58 ACE AGT
20 positive regulation of superoxide anion generation GO:0032930 9.57 AGT TGFB1
21 regulation of blood vessel diameter GO:0097746 9.55 ACE AGTR1
22 positive regulation of cholesterol esterification GO:0010873 9.54 AGT AGTR1
23 regulation of DNA binding GO:0051101 9.49 AGER TGFB1
24 positive regulation of NAD(P)H oxidase activity GO:0033864 9.48 AGT AGTR1
25 renin-angiotensin regulation of aldosterone production GO:0002018 9.46 AGT AGTR1
26 regulation of renal sodium excretion GO:0035813 9.43 AGT AGTR1
27 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.4 AGT AGTR1
28 regulation of vasoconstriction GO:0019229 9.33 ACE AGT AGTR1
29 regulation of renal output by angiotensin GO:0002019 9.32 ACE AGT
30 mononuclear cell proliferation GO:0032943 9.26 ACE TGFB1
31 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.13 ACE AGT AGTR1
32 positive regulation of cellular protein metabolic process GO:0032270 8.92 AGT AGTR1 INS TGFB1

Molecular functions related to Microvascular Complications of Diabetes 3 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.33 AGT CTGF TGFB1
2 carboxypeptidase activity GO:0004180 8.96 ACE CNDP1
3 bradykinin receptor binding GO:0031711 8.62 ACE AGTR1

Sources for Microvascular Complications of Diabetes 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....